{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:39:46Z","timestamp":1793144386850,"version":"4.5.0"},"reference-count":207,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Investigator-Initiated Study"},{"name":"Astra Zeneca"},{"name":"Astra Zeneca and Boehringer Ingelheim"},{"name":"Consultant for Sanofi Genzyme"},{"name":"Shire, Amicus, Amgen, Fresenius Medical Care and Menarini"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. Currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM have emerged, including inhibitors of renal sodium\u2013glucose co-transporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists. Apart from reducing glycaemia, these classes were reported to have other beneficial effects for the cardiovascular and renal systems, such as weight loss and blood pressure reduction. Most importantly, in contrast to all previous studies with anti-diabetic agents, a series of recent randomized, placebo-controlled outcome trials showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events and all-cause mortality, as well as progression of renal disease, in patients with type 2 DM. This document presents in detail the available evidence on the cardioprotective and nephroprotective effects of SGLT-2 inhibitors and GLP-1 analogues, analyses the potential mechanisms involved in these actions and discusses their place in the treatment of patients with CKD and DM.<\/jats:p>","DOI":"10.1093\/ndt\/gfy407","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T15:14:00Z","timestamp":1548429240000},"page":"208-230","source":"Crossref","is-referenced-by-count":190,"title":["SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA"],"prefix":"10.1093","volume":"34","author":[{"given":"Pantelis","family":"Sarafidis","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J","family":"Ferro","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario 12 de Octubre and Research Institute i+12, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz, School of Medicine, University Autonoma of Madrid, FRIAT and REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Hojs","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center and Faculty of Medicine, Maribor University, Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Khazim","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Galilee Medical Center, Nahariya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ekart","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center and Faculty of Medicine, Maribor University, Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Valdivielso","sequence":"additional","affiliation":[{"name":"Vascular and Renal Translational Research Group, Institut de Recerca Biomedica de Lleida, IRBLleida, Lleida and RedInRen, ISCIII, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Fouque","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Centre Hospitalier Lyon Sud, University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard M","family":"London","sequence":"additional","affiliation":[{"name":"Manhes Hospital and FCRIN INI-CRCTC, Manhes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Massy","sequence":"additional","affiliation":[{"name":"Hopital Ambroise Par\u00e9, Paris Ile de France Ouest (UVSQ) University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petro","family":"Ruggenenti","sequence":"additional","affiliation":[{"name":"IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Nephrology and Dialysis Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Porrini","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of La Laguna, Instituto de Tecnolog\u00eda Biom\u00e9dicas (ITB) Hospital Universitario de Canarias, Tenerife, Canary Islands, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Wiecek","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[{"name":"CNR-IFC, Clinical Epidemiology and Pathophysiology of Hypertension and Renal Diseases Unit, Ospedali Riuniti, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[{"name":"CNR-IFC, Clinical Epidemiology and Pathophysiology of Hypertension and Renal Diseases Unit, Ospedali Riuniti, Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Hornum","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"2019080909144411200_gfy407-B1","author":"WHO","year":"2016"},{"key":"2019080909144411200_gfy407-B2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.diabres.2015.05.037","article-title":"Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013","volume":"109","author":"Group IDFDA","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"2019080909144411200_gfy407-B3","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2019080909144411200_gfy407-B4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41371-018-0079-5","article-title":"The optimal blood pressure target in diabetes mellitus: a quest coming to an end?","author":"Papadopoulou","year":"2018","journal-title":"J Hum Hypertens"},{"key":"2019080909144411200_gfy407-B5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B7","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2471\/BLT.07.041715","article-title":"How can we achieve global equity in provision of renal replacement therapy?","volume":"86","author":"White","year":"2008","journal-title":"Bull World Health Organ"},{"key":"2019080909144411200_gfy407-B9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B10","first-page":"337","article-title":"Clinical Practice Guideline for the management of blood pressure in chronic kidney disease","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2019080909144411200_gfy407-B11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2013.355","article-title":"Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?","volume":"85","author":"Sarafidis","year":"2014","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B12","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc18-Sint01","article-title":"Standards of Medical Care in Diabetes-2018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B15","first-page":"e13","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2017","journal-title":"Hypertension 2018"},{"key":"2019080909144411200_gfy407-B16","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"2019080909144411200_gfy407-B17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1470320312439140","article-title":"Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression","volume":"13","author":"Sarafidis","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2019080909144411200_gfy407-B18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2337\/dc07-1572","article-title":"Is glycemic control improving in U.S. adults?","volume":"31","author":"Hoerger","year":"2008","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/1060028014540450","article-title":"Dapagliflozin for the treatment of type 2 diabetes mellitus","volume":"48","author":"Aylsworth","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2019080909144411200_gfy407-B20","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/HJH.0000000000000719","article-title":"Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?","volume":"33","author":"Imprialos","year":"2015","journal-title":"J Hypertens"},{"key":"2019080909144411200_gfy407-B21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/138161209787315693","article-title":"Effects of thiazolidinediones beyond glycaemic control","volume":"15","author":"Kalaitzidis","year":"2009","journal-title":"Curr Pharm Des"},{"key":"2019080909144411200_gfy407-B22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.clinthera.2016.04.037","article-title":"EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in type 2 diabetes mellitus","volume":"38","author":"Schernthaner","year":"2016","journal-title":"Clin Ther"},{"key":"2019080909144411200_gfy407-B23","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2019080909144411200_gfy407-B28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2019080909144411200_gfy407-B30","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B31","author":"US Food and Drug Administration. FDA approves Jardiance to Reduce Cardiovascular Death in Adults with Type 2 Diabetes [news release]","year":"2016"},{"key":"2019080909144411200_gfy407-B32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial","volume":"39","author":"Fitchett","year":"2018","journal-title":"Eur Heart J"},{"key":"2019080909144411200_gfy407-B33","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s00125-018-4644-9","article-title":"Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(R) randomised trial","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B34","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s00125-018-4630-2","article-title":"Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME(R)","volume":"61","author":"Zinman","year":"2018","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B37","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B38","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus","volume":"138","author":"Radholm","year":"2018","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2018.01.012","article-title":"The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial","volume":"200","author":"Wiviott","year":"2018","journal-title":"Am Heart J"},{"key":"2019080909144411200_gfy407-B40","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","author":"Zelniker","year":"2018","journal-title":"Lancet"},{"key":"2019080909144411200_gfy407-B41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B42","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10557-018-6786-x","article-title":"Do the SGLT-2 inhibitors offer more than hypoglycemic activity?","volume":"32","author":"Flores","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2019080909144411200_gfy407-B44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"2019080909144411200_gfy407-B45","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ Res"},{"key":"2019080909144411200_gfy407-B46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"2019080909144411200_gfy407-B48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"2019080909144411200_gfy407-B49","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrendo.2016.209","article-title":"Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME","volume":"13","author":"Sarafidis","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2019080909144411200_gfy407-B50","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/0735-1097(95)00606-0","article-title":"Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials","volume":"27","author":"Moser","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"2019080909144411200_gfy407-B51","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"2019080909144411200_gfy407-B52","first-page":"Cd003838","article-title":"Diuretics for heart failure","volume":"2","author":"Faris","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2019080909144411200_gfy407-B53","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"2019080909144411200_gfy407-B54","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/01.HYP.35.5.1025","article-title":"Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program","volume":"35","author":"Franse","year":"2000","journal-title":"Hypertension"},{"key":"2019080909144411200_gfy407-B55","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14740330903499257","article-title":"Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy","volume":"9","author":"Sarafidis","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"2019080909144411200_gfy407-B56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B58","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc18-0078","article-title":"Effects of pentoxifylline on soluble klotho concentrations and renal tubular cell expression in diabetic kidney disease","volume":"41","author":"Navarro-Gonzalez","year":"2018","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B59","doi-asserted-by":"crossref","first-page":"F647","DOI":"10.1152\/ajprenal.00090.2011","article-title":"Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy","volume":"302","author":"Sanchez-Nino","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019080909144411200_gfy407-B60","first-page":"50","article-title":"Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys","volume":"45","author":"Ortiz","year":"1997","journal-title":"J Investig Med"},{"key":"2019080909144411200_gfy407-B61","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B62","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J Am Soc Hypertens"},{"key":"2019080909144411200_gfy407-B63","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B64","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B65","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/diabetes.51.7.2025","article-title":"Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked?","volume":"51","author":"Lansang","year":"2002","journal-title":"Diabetes"},{"key":"2019080909144411200_gfy407-B66","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"2019080909144411200_gfy407-B67","first-page":"1192","article-title":"Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency","volume":"76","author":"Burge","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2019080909144411200_gfy407-B68","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME Trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","article-title":"Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics","volume":"25","author":"Puchalska","year":"2017","journal-title":"Cell Metab"},{"key":"2019080909144411200_gfy407-B70","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin's fuel hypothesis: not so soon","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab"},{"key":"2019080909144411200_gfy407-B71","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B72","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B73","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvx149","article-title":"Cardiac effects of SGLT2 inhibitors: the sodium hypothesis","volume":"114","author":"Bertero","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2019080909144411200_gfy407-B74","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2019080909144411200_gfy407-B75","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/ajh.2008.206","article-title":"Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis","volume":"21","author":"Sarafidis","year":"2008","journal-title":"Am J Hypertens"},{"key":"2019080909144411200_gfy407-B76","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of Aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B77","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B78","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2017.1328054","article-title":"A review of chemical therapies for treating diabetic hypertension","volume":"18","author":"Sarafidis","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"2019080909144411200_gfy407-B79","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2004.10.019","article-title":"Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy","volume":"45","author":"Atkins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2019080909144411200_gfy407-B81","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B82","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","article-title":"The sodium\/glucose cotransport family SLC5","volume":"447","author":"Wright","year":"2004","journal-title":"Pflugers Arch"},{"key":"2019080909144411200_gfy407-B83","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1152\/physrev.00031.2005","article-title":"Adenosine and kidney function","volume":"86","author":"Vallon","year":"2006","journal-title":"Physiol Rev"},{"key":"2019080909144411200_gfy407-B84","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B85","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019080909144411200_gfy407-B86","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm Metab Res"},{"key":"2019080909144411200_gfy407-B87","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2013renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"2019080909144411200_gfy407-B88","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","article-title":"Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse","volume":"3","author":"Salim","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"2019080909144411200_gfy407-B89","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"2019080909144411200_gfy407-B90","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas","year":"2008","journal-title":"Endocrinology"},{"key":"2019080909144411200_gfy407-B91","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfu299","article-title":"Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease","volume":"30","author":"Vlotides","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2019080909144411200_gfy407-B92","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/ki.2013.451","article-title":"Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?","volume":"86","author":"Gilbert","year":"2014","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B93","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0002-9343(82)90490-9","article-title":"The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies","volume":"72","author":"Hostetter","year":"1982","journal-title":"Am J Med"},{"key":"2019080909144411200_gfy407-B94","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00125-010-1794-9","article-title":"The clinical significance of hyperfiltration in diabetes","volume":"53","author":"Jerums","year":"2010","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B95","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"2019080909144411200_gfy407-B96","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","article-title":"Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration","volume":"57","author":"Skrtic","year":"2014","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B97","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019080909144411200_gfy407-B98","doi-asserted-by":"crossref","DOI":"10.1097\/HJH.0000000000002050","article-title":"The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume-title":"J Hypertension","author":"Piperidou","year":"2019"},{"key":"2019080909144411200_gfy407-B99","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B100","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"2019080909144411200_gfy407-B101","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2018.09.019","article-title":"SGLT1 inhibition: Pros and cons","volume":"838","author":"Tsimihodimos","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"2019080909144411200_gfy407-B102","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B103","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B104","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B105","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B106","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B107","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2337\/dc17-1551","article-title":"Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B108","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The North American in Tandem1 Study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B109","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B110","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B111","doi-asserted-by":"crossref","first-page":"522-P","DOI":"10.2337\/db18-522-P","article-title":"Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)","volume":"67","author":"Bethel","year":"2018","journal-title":"Diabetes"},{"key":"2019080909144411200_gfy407-B112","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jacc.2018.07.071","article-title":"The changing landscape of diabetes therapy for cardiovascular risk reduction: JACC state-of-the-art review","volume":"72","author":"Newman","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2019080909144411200_gfy407-B113","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/clc.23054","article-title":"The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes","volume":"41","author":"McHugh","year":"2018","journal-title":"Clin Cardiol"},{"key":"2019080909144411200_gfy407-B114","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.diabres.2018.06.008","article-title":"Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists","volume":"143","author":"Scheen","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2019080909144411200_gfy407-B115","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B116","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors' expert forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B117","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/dom.13028","article-title":"Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide","volume":"20","author":"Gerstein","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B118","author":"Trulicity\u00ae (dulaglutide) Demonstrates Superiority in Reduction of Cardiovascular Events for Broad Range of People with Type 2 Diabetes","year":"2018"},{"key":"2019080909144411200_gfy407-B119","article-title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial","author":"Bain","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B120","author":"Oral Semaglutide Demonstrates Favourable Cardiovascular Safety Profile and Significant Reduction in Cardiovascular Death and All-cause Mortality in People with Type 2 Diabetes in the PIONEER 6 trial","year":"2018"},{"key":"2019080909144411200_gfy407-B121","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"2019080909144411200_gfy407-B122","doi-asserted-by":"crossref","first-page":"131","DOI":"10.15277\/bjd.2017.147","article-title":"Diabetes medications with cardiovascular protection in the wake of EXSCEL: is there a class effect for long-acting GLP-1 receptor agonists?","volume":"17","author":"Ryder","year":"2017","journal-title":"Br J Diabetes"},{"key":"2019080909144411200_gfy407-B123","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.diabet.2017.12.009","article-title":"GLP-1 receptor agonists and cardiovascular protection: A class effect or not?","volume":"44","author":"Scheen","year":"2018","journal-title":"Diab Metab"},{"key":"2019080909144411200_gfy407-B124","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B125","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B126","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2019080909144411200_gfy407-B127","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrendo.2016.86","article-title":"Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus","volume":"12","author":"Tahrani","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2019080909144411200_gfy407-B128","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1463-1326.2012.01606.x","article-title":"Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis","volume":"14","author":"Liu","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B129","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B130","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B131","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes"},{"key":"2019080909144411200_gfy407-B132","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"key":"2019080909144411200_gfy407-B133","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B134","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","journal-title":"Obes Sci Pract"},{"key":"2019080909144411200_gfy407-B135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"2019080909144411200_gfy407-B136","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"2019080909144411200_gfy407-B137","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab"},{"key":"2019080909144411200_gfy407-B138","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2019080909144411200_gfy407-B139","first-page":"R848","article-title":"Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats","volume":"271","author":"Tang-Christensen","year":"1996","journal-title":"Am J Physiol"},{"key":"2019080909144411200_gfy407-B140","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019080909144411200_gfy407-B141","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrneph.2013.272","article-title":"The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?","volume":"10","author":"Muskiet","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2019080909144411200_gfy407-B142","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2019080909144411200_gfy407-B143","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2213-8587(15)00030-3","article-title":"Pleiotropic effects of type 2 diabetes management strategies on renal risk factors","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2019080909144411200_gfy407-B144","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00125-016-3938-z","article-title":"Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Tonneijck","year":"2016","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B145","doi-asserted-by":"crossref","first-page":"e005536","DOI":"10.1161\/JAHA.117.005536","article-title":"Gastrointestinal-renal axis: role in the regulation of blood pressure","volume":"6","author":"Yang","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2019080909144411200_gfy407-B146","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/dme.12594","article-title":"Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment","volume":"32","author":"von Scholten","year":"2015","journal-title":"Diabet Med"},{"key":"2019080909144411200_gfy407-B147","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B148","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019080909144411200_gfy407-B149","first-page":"1133","article-title":"Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects","volume":"17","author":"Sancho","year":"2006","journal-title":"Int J Mol Med"},{"key":"2019080909144411200_gfy407-B150","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/bph.13481","article-title":"Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes","volume":"173","author":"El Bekay","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2019080909144411200_gfy407-B151","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jdi.12446","article-title":"Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals","volume":"7","author":"Hirano","year":"2016","journal-title":"J Diabetes Investig"},{"key":"2019080909144411200_gfy407-B152","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"2019080909144411200_gfy407-B153","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2017.06.920","article-title":"Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits","volume":"265","author":"Sudo","year":"2017","journal-title":"Atherosclerosis"},{"key":"2019080909144411200_gfy407-B154","doi-asserted-by":"crossref","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"2019080909144411200_gfy407-B155","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2019080909144411200_gfy407-B156","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","article-title":"Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy","volume":"110","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B157","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"2019080909144411200_gfy407-B158","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"2019080909144411200_gfy407-B159","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"2019080909144411200_gfy407-B160","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.atherosclerosis.2015.03.026","article-title":"GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats","volume":"240","author":"Inoue","year":"2015","journal-title":"Atherosclerosis"},{"key":"2019080909144411200_gfy407-B161","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1479164115605000","article-title":"Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis","volume":"13","author":"Gaspari","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"2019080909144411200_gfy407-B162","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jdiacomp.2015.04.004","article-title":"Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes","volume":"29","author":"von Scholten","year":"2015","journal-title":"J Diabetes Complications"},{"key":"2019080909144411200_gfy407-B163","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.12808","article-title":"The effect of liraglutide on renal function: A randomized clinical trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B164","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"2019080909144411200_gfy407-B165","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2019080909144411200_gfy407-B166","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000453531","article-title":"An overview of errors and flaws of estimated GFR versus True GFR in patients with diabetes mellitus","volume":"136","author":"Luis-Lima","year":"2017","journal-title":"Nephron"},{"key":"2019080909144411200_gfy407-B167","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41581-018-0055-x","article-title":"Renoprotective effects of dulaglutide in patients with T2DM and CKD","volume":"14","author":"Sorensen","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2019080909144411200_gfy407-B168","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The potential for renoprotection with incretin-based drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B169","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2017.10.049","article-title":"Effects of incretin-based therapies on renal function","volume":"818","author":"Tsimihodimos","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"2019080909144411200_gfy407-B171","doi-asserted-by":"crossref","first-page":"e13102","DOI":"10.14814\/phy2.13102","article-title":"Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers","volume":"5","author":"Bremholm","year":"2017","journal-title":"Physiol Rep"},{"key":"2019080909144411200_gfy407-B172","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3390\/jcm4101866","article-title":"Nephroprotection by hypoglycemic agents: do we have supporting data?","volume":"4","author":"Gorriz","year":"2015","journal-title":"J Clin Med"},{"key":"2019080909144411200_gfy407-B173","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/ki.2014.398","article-title":"Incretin-based drugs and renoprotection-is hyperfiltration key?","volume":"87","author":"Tonneijck","year":"2015","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B174","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00592-017-1031-9","article-title":"Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"54","author":"Dicembrini","year":"2017","journal-title":"Acta Diabetol"},{"key":"2019080909144411200_gfy407-B175","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.diabres.2013.03.018","article-title":"Euglycemic progression: worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities","volume":"100","author":"Shurter","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2019080909144411200_gfy407-B176","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2019080909144411200_gfy407-B177","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"2019080909144411200_gfy407-B178","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2019080909144411200_gfy407-B179","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.2337\/dcS13-2004","article-title":"Do GLP-1-based therapies increase cancer risk?","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B180","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2019080909144411200_gfy407-B181","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2019080909144411200_gfy407-B182","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2019080909144411200_gfy407-B183","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pcad.2009.05.003","article-title":"Heart rate as a risk factor for cardiovascular disease","volume":"52","author":"Perret-Guillaume","year":"2009","journal-title":"Prog Cardiovasc Dis"},{"key":"2019080909144411200_gfy407-B184","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ahj.2009.12.029","article-title":"Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women","volume":"159","author":"Cooney","year":"2010","journal-title":"Am Heart J"},{"key":"2019080909144411200_gfy407-B185","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2019080909144411200_gfy407-B186","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2337\/dc15-1437","article-title":"Effects of GLP-1 receptor agonists on heart rate and the autonomic nervous system using holter electrocardiography and power spectrum analysis of heart rate variability","volume":"39","author":"Nakatani","year":"2016","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B187","article-title":"Evaluation of the effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE)"},{"key":"2019080909144411200_gfy407-B188","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"2019080909144411200_gfy407-B189","author":"Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA\u00ae (canagliflozin) is Being Stopped Early for Positive Efficacy Findings"},{"key":"2019080909144411200_gfy407-B190","article-title":"A study to evaluate the effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with chronic kidney disease (Dapa-CKD)"},{"key":"2019080909144411200_gfy407-B191","article-title":"EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin"},{"key":"2019080909144411200_gfy407-B192","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(18)32348-1","article-title":"HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?","volume":"392","author":"Mafham","year":"2018","journal-title":"Lancet"},{"key":"2019080909144411200_gfy407-B193","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B194","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"G\u00e6de","year":"2008","journal-title":"N Engl J Med"},{"key":"2019080909144411200_gfy407-B195","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2019080909144411200_gfy407-B196","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"2019080909144411200_gfy407-B197","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"2019080909144411200_gfy407-B198","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ndt\/gfv100","article-title":"Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL\/min","volume":"30 (Suppl 2)","author":"Guideline Development Group","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2019080909144411200_gfy407-B199","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cll.2006.06.005","article-title":"Microalbuminuria","volume":"26","author":"Khosla","year":"2006","journal-title":"Clin Lab Med"},{"key":"2019080909144411200_gfy407-B200","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/ki.1996.265","article-title":"The hyperfiltration theory: a paradigm shift in nephrology","volume":"49","author":"Brenner","year":"1996","journal-title":"Kidney Int"},{"key":"2019080909144411200_gfy407-B201","author":"Jardiance\u00ae. Summary of Product Characteristics","year":"2014"},{"key":"2019080909144411200_gfy407-B202","author":"Invokana\u00ae. Summary of Product Characteristics","year":"2013"},{"key":"2019080909144411200_gfy407-B203","author":"Invokana\u00ae. Highlights of Prescribing Information","year":"2013"},{"key":"2019080909144411200_gfy407-B204","author":"Jardiance\u00ae. Highlights of Prescribing Information","year":"2014"},{"key":"2019080909144411200_gfy407-B205","author":"Forxiga\u00ae. Summary of Product Characteristics","year":"2012"},{"key":"2019080909144411200_gfy407-B206","author":"Farxiga\u00ae. Highlights of Prescribing Information","year":"2014"},{"key":"2019080909144411200_gfy407-B207","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1681\/ASN.2014070688","article-title":"Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis","volume":"26","author":"Heerspink","year":"2015","journal-title":"J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/2\/208\/29113869\/gfy407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T20:05:13Z","timestamp":1662840313000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/2\/208\/5307730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":207,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,6]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy407","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}